Loading organizations...
§ Private Profile · San Diego, CA, USA
clinical-stage biotechnology company developing novel therapeutics for immunological and inflammatory diseases.
ImageneBio, formerly Inmagene Biopharmaceuticals, is a San Diego-based clinical-stage biotechnology company focused on developing novel therapeutics for immunological, autoimmune, and inflammatory diseases. Its lead asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody being tested for atopic dermatitis and alopecia areata, alongside additional candidates including a reversible BTK inhibitor and an anti-IL-36R monoclonal antibody. In July 2025, Inmagene completed a merger with Ikena Oncology to create ImageneBio, which began trading under ticker IMA. The company has raised approximately $177.8 million in total funding, employs between 51 and 200 individuals, and is backed by key investors such as Deep Track Capital, Foresite Capital, and RTW Investments. Dr. Kristin Yarema serves as CEO, while Jonathan Wang founded the company in 2019. Its business model centers on the company operates as a clinical-stage biotech funded through venture capital and private placements rather than product revenue.
Inmagene Biopharmaceuticals has raised $121.0M across 2 funding rounds.
Inmagene Biopharmaceuticals has raised $121.0M in total across 2 funding rounds.
Inmagene Biopharmaceuticals has raised $121.0M in total across 2 funding rounds.
Inmagene Biopharmaceuticals's investors include Vertex Ventures, VMS, Kunlun Capital, SCVC.
Inmagene Biopharmaceuticals has raised $121.0M across 2 funding rounds. Most recently, it raised $100.0M Series C in June 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2021 | $100M Series C | — | Vertex Ventures, VMS | Announced |
| Nov 9, 2020 | $21M Series B | — | Kunlun Capital, Scvc | Announced |